Kashim RM, Newton P, Ojo O. Diabetic Retinopathy Screening a Systematic Review on Patients’ Non-Attendance. Int J Environ Res Public Health. 2018;15(1):157.
Feldman-Billard S, Larger E, Massin P. Stand Screening Surveillance O Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes. Diabetes Metab. 2018;44(1):4–14.
Platania CBM, Maisto R, Trotta MC, D’Amico M, Rossi S, Gesualdo C, et al. Retinal and circulating miRNA expression patterns in diabetic retinopathy: An in silico and in vivo approach. Br J Pharmacol. 2019;176(13):2179–94.
Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Global Health. 2017;5(12):E1221–34.
Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global Prevalence and Major Risk Factors of Diabetic Retinopathy. Diabetes Care. 2012;35(3):556–64.
Ting DSW, Cheung GCM, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Experiment Ophthalmol. 2016;44(4):260–77.
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124–36.
P S, J Y, KY C, E T, health RIJJog. Prevalence, risk factors and burden of diabetic retinopathy in China: a systematic review and meta-analysis. 2018;8(1):010803.
Lin KY, Hsih WH, Lin YB, Wen CY, Chang TJ. Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. J Diab Investigation.
Wong TY, Sabanayagam C. Strategies to Tackle the Global Burden of Diabetic Retinopathy: From Epidemiology to Artificial Intelligence. Ophthalmologica. 2020;243(1):9–20.
Rajalakshmi R, Prathiba V, Arulmalar S, Usha M. Review of retinal cameras for global coverage of diabetic retinopathy screening. Eye. 2021;35(1):162–72.
Xie YC, Nguyen QD, Hamzah H, Lim G, Bellemo V, Gunasekeran DV, et al. Artificial intelligence for teleophthalmology-based diabetic retinopathy screening in a national programme: an economic analysis modelling study. Lancet Digital Health. 2020;2(5):E240–9.
Ting DSW, Cheung CY, Lim G, Tan GSW, Quang ND, Gan A, et al. Development and Validation of a Deep Learning System for Diabetic Retinopathy and Related Eye Diseases Using Retinal Images From Multiethnic Populations With Diabetes. JAMA. 2017;318(22):2211–23.
Dismuke C. Progress in examining cost-effectiveness of AI in diabetic retinopathy screening. Lancet Digital Health. 2020;2(5):E212–3.
He J, Cao TY, Xu FP, Wang SS, Tao HQ, Wu T, et al. Artificial intelligence-based screening for diabetic retinopathy at community hospital. Eye. 2020;34(3):572–6.
Li ZX, Zhang J, Fong N, He MG. Using artificial intelligence as an initial triage strategy in diabetic retinopathy screening program in China. Zhonghua Yi Xue Za Zhi. 2020;100(48):3835–40.
Ming S, Xie K, Lei X, Yang Y, Zhao Z, Li S, et al. Evaluation of a novel artificial intelligence-based screening system for diabetic retinopathy in community of China: a real-world study. Int Ophthalmol. 2021;41(4):1291–9.
Shah A, Clarida W, Amelon R, Hernaez-Ortega MC, Navea A, Morales-Olivas J, et al. Validation of Automated Screening for Referable Diabetic Retinopathy With an Autonomous Diagnostic Artificial Intelligence System in a Spanish Population. J Diabetes Sci Technol. 2021;15(3):655–63.
Bhaskaranand M, Ramachandra C, Bhat S, Cuadros J, Nittala MG, Sadda SR, et al. The Value of Automated Diabetic Retinopathy Screening with the EyeArt System: A Study of More Than 100,000 Consecutive Encounters from People with Diabetes. Diabetes Technol Ther. 2019;21(11):635–43.
Ming S, Xie KP, Lei X, Yang YR, Zhao ZX, Li SY, et al. Evaluation of a novel artificial intelligence-based screening system for diabetic retinopathy in community of China: a real-world study. Int Ophthalmol. 2021;41(4):1291–9.
Li YZ, Teng D, Shi XG, Qin GJ, Qin YF, Quan HB, Prevalence of diabetes recorded in mainland China using, et al. diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ-Brit Med J. 2018;2020:369.
Wong TY, Sun J, Kawasaki R, Ruamviboonsuk P, Gupta N, Lansingh VC, et al. Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings. Ophthalmology. 2018;125(10):1608–22.
He J, Cao T, Xu F, Wang S, Tao H, Wu T, et al. Artificial intelligence-based screening for diabetic retinopathy at community hospital. Eye (Lond). 2020;34(3):572–6.
Li M, Wang GY, Xia HH, Tang XY, Feng ZQ, et al. Clinical evaluation of artificial intelligence system based on fundus photograph in diabetic retinopathy screening. Chin J Exp Ophthalmol. 2019;37(8):663–8.
Khalaf SS, Al-Bdour MD, Al-Till MI. Clinical biomicroscopy versus fluorescein angiography: Effectiveness and sensitivity in detecting diabetic retinopathy. Eur J Ophthalmol. 2007;17(1):84–8.
Zhang WJ, Wei M. The evaluation of the mortality and life expectancy of chinese population. Population Journal. 2016;38(03):18–28.
Tung TH, Chen SJ, Shih HC, Chou P, Li AF, Lee FL, et al. Assessing the natural course of diabetic retinopathy: A population-based study in Kinmen. Taiwan Ophthalmic Epidemiology. 2006;13(5):327–33.
Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med. 1996;124(1 Pt 2):164–9.
Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA-J Am Med Assoc. 2000;283(7):889–96.
Rachapelle S, Legood R, Alavi Y, Lindfield R, Sharma T, Kuper H, et al. The Cost-Utility of Telemedicine to Screen for Diabetic Retinopathy in India. Ophthalmology. 2013;120(3):566–73.
Smith DH, Johnson ES, Russell A, Hazlehurst B, Muraki C, Nichols GA, et al. Lower visual acuity predicts worse utility values among patients with type 2 diabetes. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2008;17(10):1277–84.
Yfantopoulos J, Chantzaras A. Health-related quality of life and health utilities in insulin-treated type 2 diabetes: the impact of related comorbidities/complications. Eur J Health Economics. 2020;21(5):729–43.
Tang J, Liang Y, O’Neill C, Kee F, Jiang J, Congdon N. Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model. Lancet Glob Health. 2019;7(7):E968–78.
Tang J, Liang Y, O’Neill C, Kee F, Jiang J, Congdon N. Cost-effectiveness and cost-utility of population-based glaucoma screening in China a decision-analytic Markov model. Lancet Global Health. 2019;7(7):e968–78.
Zhao Q, Wang L, Tao T, Xu B. Impacts of the “transport subsidy initiative on poor TB patients” in Rural China: a patient-cohort based longitudinal study in rural China. PLoS One. 2013;8(11):e82503.
Sluiter RL, Janzing JGE, van der Wilt GJ, Kievit W, Teichert M. An economic model of the cost-utility of pre-emptive genetic testing to support pharmacotherapy in patients with major depression in primary care. Pharmacogenomics J. 2019;19(5):480–9.
Hutubessy R, Chisholm D, Edejer TT-T. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost effectiveness and resource allocation: C/E. 2003;1(1):8.
World Health O, Baltussen RMPM, Adam T, Tan-Torres Edejer T, Hutubessy RCW, Acharya A, et al. Making choices in health : WHO guide to cost-effectiveness analysis / edited by T. Tan-Torres Edejer ... [et al]. Geneva: World Health Organization; 2003.
Tufail A, Rudisill C, Egan C, Kapetanakis V, Salas-Vega S, Owen C, et al. Automated Diabetic Retinopathy Image Assessment Software: Diagnostic Accuracy and Cost-Effectiveness Compared with Human Graders. Ophthalmology. 2017;124(3):343–51.
Scotland G, McNamee P, Philip S, Fleming A, Goatman K, Prescott G, et al. Cost-effectiveness of implementing automated grading within the national screening programme for diabetic retinopathy in Scotland. Bri J Ophthalmol. 2007;91(11):1518–23.
Xie Y, Nguyen QD, Hamzah H, Lim G, Bellemo V, Gunasekeran DV, et al. Artificial intelligence for teleophthalmology-based diabetic retinopathy screening in a national programme: an economic analysis modelling study. Lancet Digital Health. 2020;2(5):E240–9.
Fuller SD, Hu J, Liu JC, Gibson E, Gregory M, Kuo J, et al. Five-Year Cost-Effectiveness Modeling of Primary Care-Based, Nonmydriatic Automated Retinal Image Analysis Screening Among Low-Income Patients with Diabetes. J Diabetes Sci Technol. 2020:1932296820967011.
Thomas RL, Winfield TG, Prettyjohns M, Dunstan FD, Cheung WY, Anderson PM, et al. Cost-effectiveness of biennial screening for diabetes related retinopathy in people with type 1 and type 2 diabetes compared to annual screening. Eur J Health Econ. 2020;21(7):993–1002.
Nathan DM, Bebu I, Hainsworth D, Klein R, Tamborlane W, Lorenzi G, et al. Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. N Engl J Med. 2017;376(16):1507–16.
Eleuteri A, Fisher AC, Broadbent DM, Garcia-Finana M, Cheyne CP, Wang A, et al. Individualised variable-interval risk-based screening for sight-threatening diabetic retinopathy: the Liverpool Risk Calculation Engine. Diabetologia. 2017;60(11):2174–82.
Scotland G, McKeigue P, Philip S, Leese GP, Olson JA, Looker HC, et al. Modelling the cost-effectiveness of adopting risk-stratified approaches to extended screening intervals in the national diabetic retinopathy screening programme in Scotland. Diabetic Med. 2016;33(7):886–95.
Scanlon PH, Aldington SJ, Leal J, Luengo-Fernandez R, Oke J, Sivaprasad S, et al. Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. Health Technol Assessment. 2015;19(74):1.
Lian JX, McGhee SM, Gangwani RA, Chan CKW, Lam CLK, Yap MKH, et al. The impact of a co-payment on the cost- effectiveness of screening for diabetic retinopathy. J Public Health. 2016;38(4):782–92.